- Home
- KEY vs TEVA Comparison
KEY vs TEVA Comparison
Compare KEY & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEY
- TEVA
- Stock Information
- Founded
- KEY 1825
- TEVA 1901
- Country
- KEY United States
- TEVA Israel
- Employees
- KEY 17406
- TEVA N/A
- Industry
- KEY Major Banks
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- KEY Finance
- TEVA Health Care
- Exchange
- KEY Nasdaq
- TEVA Nasdaq
- Market Cap
- KEY 17.3B
- TEVA 18.4B
- IPO Year
- KEY N/A
- TEVA N/A
- Fundamental
- Price
- KEY $15.85
- TEVA $16.77
- Analyst Decision
- KEY Buy
- TEVA Strong Buy
- Analyst Count
- KEY 19
- TEVA 7
- Target Price
- KEY $18.95
- TEVA $25.14
- AVG Volume (30 Days)
- KEY 12.5M
- TEVA 14.1M
- Earning Date
- KEY 07-21-2025
- TEVA 05-07-2025
- Dividend Yield
- KEY 5.17%
- TEVA N/A
- EPS Growth
- KEY N/A
- TEVA N/A
- EPS
- KEY N/A
- TEVA N/A
- Revenue
- KEY $4,464,000,000.00
- TEVA $16,616,000,000.00
- Revenue This Year
- KEY $74.95
- TEVA $5.69
- Revenue Next Year
- KEY $6.35
- TEVA N/A
- P/E Ratio
- KEY N/A
- TEVA N/A
- Revenue Growth
- KEY N/A
- TEVA 3.82
- 52 Week Low
- KEY $12.73
- TEVA $12.47
- 52 Week High
- KEY $20.04
- TEVA $22.80
- Technical
- Relative Strength Index (RSI)
- KEY 52.89
- TEVA 51.29
- Support Level
- KEY $15.28
- TEVA $16.68
- Resistance Level
- KEY $16.08
- TEVA $18.28
- Average True Range (ATR)
- KEY 0.32
- TEVA 0.63
- MACD
- KEY -0.06
- TEVA -0.04
- Stochastic Oscillator
- KEY 39.86
- TEVA 20.11
About KEY KeyCorp
With assets of over $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.